AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
AIM Vaccine Co., Ltd. has announced the submission of pre-application for clinical trials of two mRNA vaccines targeting Respiratory Syncytial Virus and Shingles/Herpes Zoster. The move aligns with the company’s strategy to leverage mRNA technology and tackle diseases with significant market potential, as RSV vaccines are expected to hit a global market size of $16.7 billion by 2030, and Shingles vaccines may reach $23.9 billion. AIM Vaccine is at the forefront of mRNA vaccine development in China, with a robust R&D system and GMP-compliant production facilities poised to rapidly industrialize and commercialize these vaccines upon clinical approval.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.